Saint-Laurent du Var, France, September 3, β Horus Pharma , an independent laboratory specialized in ophthalmology, announces today the launch of a new 15ml bottle of Neovis Total Multi for the French, Belgian and Spanish markets. The product is prescribed as third-line therapy for the treatment of dry eyes with keratitis or dry keratoconjunctivitis, following unsuccessful treatment with low-viscosity tear substitutes and gels.
Neovis Total Multi is an artificial tear emulsion that acts on the entire tear film, including the lipid layer. Preservative and surfactant free, it increases the thickness of the tear film and has both anti-inflammatory and antioxidant effects. The new bottle is fitted with a silicone membrane nozzle, which prevents microbial contamination of the emulsion, while also keeping it sterile.
It can be used for four months after opening, which is equivalent to the average length of treatment. Dry eyes is a disorder of the tear film due to the deficiency or excessive evaporation of tears.
This can lead to ocular surface changes in the area of the palpebral fissure and may be accompanied by symptoms of ocular discomfort. The symptoms of dry eye syndrome can include pain, itching, foreign body sensation, burning, photophobia and general discomfort. Neovis Total Multi 15ml has been marketed in France since February , on prescription by ophthalmologists. Horus Pharma is an independent ophthalmology laboratory that develops, patents and markets preservative-free health products for eyes and eyelids.
Horus Pharma is among the market leaders in France in its sector. The company distributes its products in France and worldwide through its subsidiaries in Spain, the Netherlands, Belgium and Luxembourg, and through distribution agreements in other countries.
